+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The Corporate Reputation of Pharma in 2020 - The Patient Perspective - Mental Health Edition: The Views of 80 Mental Health Patient Groups

  • Report

  • 49 Pages
  • November 2021
  • Region: Global
  • PatientView
  • ID: 5174359

The results of an independent survey of 80 mental health patient groups in 2020.   Collectively, these patient groups reached out to  45,500 people with various mental-health conditions during 2020. The respondent mental-health patient groups commented on 7 companies, selecting those with the “Best” corporate reputation in 2020, and which were “Best” at responding to Covid-19 in 2020. 

Summary of findings 

Findings from the 2020 ‘Corporate Reputation’ survey show that many members of the population feared their mental health to be suffering during the pandemic. Mental-health patient groups responding to the survey reported increased contact during the year with individuals seeking help for mental-health issues. Yet respondent mental-health patient groups described, in their commentaries to the survey, how pharma’s reaction to the pandemic was, for the most part, muted. They pointed out several ways in which pharma companies could have provided help to mental-health communities.

About the survey of 80 mental-health patient groups: 

When? The survey was conducted in November 2020-February 2021, when key events of the pandemic will have influenced the opinions of respondent mental-health patient groups. 

The questionnaire? Pharma was assessed across a wide range of its activities important to patients and patient groups, including a new indicator for 2020 - pharma’s effectiveness at tackling Covid-19 during that year. 

How were the companies assessed? The indicators used to measure a company’s corporate reputation: 
1. Covid-19 response [new for the 2020 survey]
2. Patient centricity
3. Patient information
4. Patient safety
5. High-quality products
6.i. Transparency: pricing
6.ii. Transparency: clinical-trial data
6.iii. Transparency: funding of external stakeholders
7. Integrity
8. Quality of relationships with patient groups
9. Providing services ‘beyond the pill’
10.i. Engaging patients in research
10.ii. Engaging patients in development.

Table of Contents


1 Executive summary
8 Relationships that mental health patient groups have with pharma
11 Industry-wide findings
17 The corporate-reputation rankings of 7 pharma companies, 2020 (v. 2019), as assessed by mental health patient groups familiar with the companies
33 The corporate-reputation rankings of 3 pharma companies, 2020, as assessed by mental health patient groups that work/partner with the companies
49 Profiles of the 7 companies, 2020 (v. 2019)
APPENDICES
I Profiles of respondent mental health patient groups, 2020
II List of respondent mental health patient groups that wished to be attributed, 2020
III What respondent mental health patient groups say about pharma (and how the industry can improve), 2020/2021

TABLES AND CHARTS
2 The ten indicators used to measure corporate reputation, 2020
3 Percentage of respondent patient groups stating that pharma had an “Excellent” or “Good” corporate reputation, 2015-2020: mental health v. all therapy areas
6 Percentage of respondent patient groups stating that pharma had an “Excellent” or “Good” at innovation, 2014-2020: mental health v. all therapy areas
6 Percentage of respondent patient groups stating that pharma was “Excellent” or “Good” at providing high-quality, useable products, 2014-2020: mental health v. all therapy areas
9 Respondent mental health patient groups: their familiarity, and partnerships, with pharma companies, 2020
10 The types of working relationships that respondent mental health patient groups have with pharma, 2020
12 The corporate reputation of the pharmaceutical industry, 2020 v. 2019-compared with that of other healthcare sectors (percentage of respondent mental health patient groups stating “Excellent” or “Good”)
12 The corporate reputation of the pharmaceutical industry, 2015-2020-mental health patient groups v. patient groups from all therapy areas (percentage of respondent patient groups stating “Excellent” or “Good”)
13 How good or bad the pharmaceutical industry was in 2020 v. 2019 at carrying out specific activities important to patients (percentage of respondent mental health patient groups stating “Excellent” or “Good”)
14 The pharmaceutical industry’s effectiveness at tackling Covid-19 in 2020-mental health v. therapy wide (percentage of respondent patient groups stating “Excellent” or “Good”)
15  How good or bad the pharmaceutical industry was at carrying out specific activities important to patients, 2014-2020 (percentage of respondent mental health patient groups stating “Excellent” or “Good”)
17  The rankings of 7 individual pharma companies, 2020 v. 2019-as assessed by respondent mental health patient groups familiar with the company
33  The rankings of 3 individual pharma companies, 2020 v. 2019-as assessed by respondent mental health patient groups that work/partner with the company

TABLES AND CHARTS
49 CHARTS AND TABLES FOR EACH OF THE 7 COMPANIES
  • The number of respondent mental health patient groups familiar with the company, 2020.
  • The number of respondent mental health patient groups saying that they had a working/partnering relationship with the company, 2020.
  • The profile of the respondent mental health patient groups familiar with the company (the number of patients reached; country headquarters; specialties; and geographic remit), 2020.
  • The types of relationships that the company had with its mental health patient-group partners, 2020.
  • Company performance at the individual indicators of corporate reputation in 2020-as assessed by respondent mental health patient groups familiar, and which partner/work, with the company.
  • Competitors’ relationships in 2020 with the respondent mental health patient groups with which the company partners/works.
  • Overall rankings for the company-as assessed by respondent mental health patient groups familiar with the company, 2020 (v. 2019).
  • Overall rankings for the company-as assessed by respondent mental health patient groups that work/partner with the company, 2020 (v. 2019).
  • Company rankings for each of the indicators of corporate reputation-as assessed by respondent mental health patient groups familiar, or working/partnering, with the company, 2020 (v. 2019).
  • Snapshot view: where the company sits in the corporate tiers for each of the indicators (in the higher, the middle, or the lower tier)-as assessed by respondent mental health patient groups familiar with the company.
  • The company’s overall Patient Corporate Reputation Index (PCRI), 2015-2020, as assessed by respondent mental health patient groups familiar with the company.





















Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie
  • Eli Lilly
  • Janssen
  • Lundbeck
  • Otsuka
  • Sandoz
  • Teva